D-1566-2020 Class II Terminated

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-1566-2020 was initiated by Teva Pharmaceuticals USA on Aug 24, 2020 and is designated Class II. Reason for recall: Sub-Potent Drug: Out of specification test results for potency (below specification). The recall status is terminated (terminated Dec 16, 2021). Affected quantity: 38,487 bottles.

Recall details

Product Type
Drugs
Report Date
Sep 16, 2020
Initiation Date
Aug 24, 2020
Termination Date
Dec 16, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
38,487 bottles

Product description

Cephalexin for Oral Suspension, USP 250 mg per 5 mL, For Reconstitution, For Oral Use Only, Rx Only, 100 mL bottle when mixed, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 0093-4177-73.

Reason for recall

Sub-Potent Drug: Out of specification test results for potency (below specification).

Distribution pattern

Nationwide in the U.S. and Puerto Rico.

Code information

Lot #: 30310638A, Exp. 02/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1566-2020
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1566-2020. Report a data issue: hello@regdatalab.com.